Xiu Huang

Ms. Xiu Huang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XHXiu Huang
Xiu Huang
YJYong Jia
Yong Jia
XZXiaoyu Zhu
Xiaoyu Zhu
YZYangyang Zhang
Yangyang Zhang
LJLili Jiang
Lili Jiang
YDYujun Du
Yujun Du
Objective. To assess the benefits of statins on lipid profile in kidney transplant recipients via a meta‐analysis. Methods. We systematically identified peer‐reviewed clinical trials, review articles, and treatment guidelines from PubMed, Embase, the Cochrane Library, Wanfang, Chinese National Knowledge Infrastructure (CNKI), SinoMed (CBM), and Chongqing VIP databases from inception to April 2019. In the analysis, only randomized controlled clinical trials performed in human were included. Results. Eight articles were included in the analysis, involving 335 kidney transplant recipients who received statins and 350 kidney transplant patients as the control group. Results revealed that statins improved the lipid profile of kidney transplant recipients. Specifically, statin therapy significantly reduced total cholesterol and low‐density lipoprotein cholesterol. However, it had no effects on high‐density lipoprotein cholesterol and triglyceride levels. Conclusions. The present study provides valuable knowledge on the potential benefits of statins in kidney transplant recipients. This meta‐analysis shows that statin therapy modifies the lipid profile in this patient population.

2 May 2025 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
XHXiu Huang
Xiu Huang
XRXiya Ren
Xiya Ren
LZLimei Zhao
Limei Zhao
YHYajie Hao
Yajie Hao
ZZZhibo Zhao
Zhibo Zhao
XZXiaoshuang Zhou
Xiaoshuang Zhou

10 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
XHXiu Huang
Xiu Huang
YJYong Jia
Yong Jia
XZXiaoyu Zhu
Xiaoyu Zhu
YZYangyang Zhang
Yangyang Zhang
LJLili Jiang
Lili Jiang
YDYujun Du
Yujun Du
Objective: To assess the benefits of statins on lipid profile in kidney transplant recipients via a meta-analysis. Methods: We systematically identified peer-reviewed clinical trials, review articles, and treatment guidelines from PubMed, Embase, the Cochrane Library, Wanfang, Chinese National Knowledge Infrastructure (CNKI), SinoMed (CBM), and Chongqing VIP databases from inception to April 2019. In the analysis, only randomized controlled clinical trials performed in human were included. Results: Eight articles were included in the analysis, involving 335 kidney transplant recipients who received statins and 350 kidney transplant patients as the control group. Results revealed that statins improved the lipid profile of kidney transplant recipients. Specifically, statin therapy significantly reduced total cholesterol and low-density lipoprotein cholesterol. However, it had no effects on high-density lipoprotein cholesterol and triglycerides levels. Conclusions: The present study provides valuable knowledge on the potential benefits of statins in kidney transplant recipients. This meta-analysis shows that statin therapy modifies the lipid profile in this patient population.

7 January 2021 in Research Square
Verified
Preprint
Open access
PDF file
XHXiu Huang
Xiu Huang
NDNa Du
Na Du
JHJiaxue He
Jiaxue He
YDYujun Du
Yujun Du
Background: Actinomycosis is a rare cause of unexplained origin fever (FUO). The NGS, particularly in cases of FUO in conventional microbiology, is a promising and advantageous technology for earlier diagnosis and more success. It gives new insights in the management of FUO, especially in infectious diseases.Case presentation: We present a case of a 71-year-old woman who had FUO that the etiology was endobronchial actinomycosis eventually diagnosed by next-generation sequencing of bronchoalveolar lavage fluid. She was admitted to the our department with intermittent fever up to 40.0℃, chills, cough with white sputum, chest distress and slightly dyspnea over one month. According to special clinical course and laboratory data of the patient, she was given intravenous sulbenicillin sodium for 11 days and oral amoxicillin at 500 mg every 8 h for another 1 month. When she returned for follow-up, she reported a notable improvement in her cough, dyspnea, sputum production and fever that was completely absent.Conclusion: In obscure causes of FUO, clinicians should consider the possibility of thoracic actinomycosis and actively use next-generation sequencing to help diagnose.

4 November 2024
Verified
Preprint
Open access
XHXiu Huang
Xiu Huang
XRXiya Ren
Xiya Ren
LZLimei Zhao
Limei Zhao
YHYajie Hao
Yajie Hao
ZZZhibo Zhao
Zhibo Zhao
XZXiaoshuang Zhou
Xiaoshuang Zhou
Kidney diseases, characterized by renal dysfunction, are among the leading causes of death worldwide. Preventing and treating kidney diseases is important for reducing their associated morbidity and mortality. Moderate physical exercise has been recognized to be advantageous for kidney health. Irisin is an exercise-induced myokine identified in 2012. It plays an important role in energy and bone metabolism, oxidative stress reduction, anti-inflammatory processes, prevention of cell death, and cardiovascular protection. However, the relationship between irisin and kidney disease has not been fully elucidated. This review explores the role of irisin as a biomarker in the diagnosis of kidney diseases and their associated complications, elucidating the mechanisms through which it participates in various cell death pathways, such as apoptosis, autophagy, pyroptosis and ferroptosis. Furthermore, the levles of irisin secretion are discussed to provide a basis for the preventing and treating kidney diseases, as well as therapeutic guidance for developing new and promising intervention strategies.

9 September 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
XHXiu Huang
Xiu Huang
XRXiya Ren
Xiya Ren
YHYajie Hao
Yajie Hao
LZLimei Zhao
Limei Zhao
ZZZhibo Zhao
Zhibo Zhao
XZXiaoshuang Zhou
Xiaoshuang Zhou
Background: Sleep-related problems are common among patients receiving dialysis for end-stage renal disease (ESRD), while pharmacological management may be complicated by comorbidities, polypharmacy, and altered drug clearance. This systematic review and meta-analysis evaluated the effects of non-pharmacological interventions on sleep-related outcomes, anxiety symptoms, depressive symptoms, and fatigue symptoms in this population. Methods: PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to February 2026. The prespecified eligibility criterion was restricted to randomized controlled trials (RCTs) involving adults with ESRD receiving hemodialysis or peritoneal dialysis and reporting an eligible sleep-related outcome. One quasi-cluster randomized trial was retained as a documented protocol deviation. Standardized mean differences (SMDs) calculated using Hedges’ g and 95% confidence intervals (CIs) were pooled using random-effects models with restricted maximum-likelihood estimation and the Hartung–Knapp–Sidik–Jonkman adjustment (REML–HKSJ). Risk of bias was assessed using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2), and evidence certainty was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. PROSPERO: CRD420251123449. Results: The 19 RCTs and one quasi-cluster randomized trial contributed an effective sample size of 1294 participants. The pooled estimate favored non-pharmacological interventions for sleep-related outcomes (Hedges’ g = −0.820, 95% CI −1.188 to −0.451; p = 0.0002), with substantial heterogeneity (I2 = 83.1%; τ2 = 0.4879). The 95% prediction interval (PI) ranged from −2.325 to 0.685. The pooled effects on anxiety symptoms (Hedges’ g = −0.29, 95% CI −0.99 to 0.41; p = 0.219), depressive symptoms (Hedges’ g = −0.64, 95% CI −2.32 to 1.04; p = 0.313), and fatigue symptoms (Hedges’ g = −0.41, 95% CI −0.93 to 0.11; p = 0.087) were not statistically significant. Effect estimates differed significantly by comparator type (Q-between = 11.28, df = 2; p = 0.0036). Conclusions: Non-pharmacological interventions may improve sleep-related outcomes in patients receiving dialysis for ESRD. However, substantial heterogeneity and a prediction interval crossing the null value limit confidence in the pooled estimate. Current evidence does not demonstrate clear benefits for anxiety symptoms, depressive symptoms, or fatigue symptoms.